Logo image of CHS.CA

COMPREHENSIVE HEALTHCARE SYS (CHS.CA) Stock Fundamental Analysis

TSX-V:CHS - TSX Venture Exchange - CA2046631081 - Common Stock - Currency: CAD

0.015  0 (0%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to CHS. CHS was compared to 7 industry peers in the Health Care Technology industry. CHS has a bad profitability rating. Also its financial health evaluation is rather negative. CHS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CHS has reported negative net income.
CHS.CA Yearly Net Income VS EBIT VS OCF VS FCFCHS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -1M -2M -3M -4M -5M

1.2 Ratios

The Return On Assets of CHS (-599.10%) is worse than 85.71% of its industry peers.
Industry RankSector Rank
ROA -599.1%
ROE N/A
ROIC N/A
ROA(3y)-244.18%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHS.CA Yearly ROA, ROE, ROICCHS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 200 -200 -400 -600 -800

1.3 Margins

With a Gross Margin value of 30.11%, CHS perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
CHS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CHS.CA Yearly Profit, Operating, Gross MarginsCHS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 -50 -100

More info and screens

0

2. Health

2.1 Basic Checks

CHS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CHS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for CHS is higher compared to a year ago.
CHS.CA Yearly Shares OutstandingCHS.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 20M 40M 60M 80M 100M
CHS.CA Yearly Total Debt VS Total AssetsCHS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 1M 2M 3M 4M

2.2 Solvency

CHS has an Altman-Z score of -71.69. This is a bad value and indicates that CHS is not financially healthy and even has some risk of bankruptcy.
CHS has a Altman-Z score of -71.69. This is in the lower half of the industry: CHS underperforms 71.43% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -71.69
ROIC/WACCN/A
WACC9.88%
CHS.CA Yearly LT Debt VS Equity VS FCFCHS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 -2M -4M

2.3 Liquidity

A Current Ratio of 0.04 indicates that CHS may have some problems paying its short term obligations.
CHS has a worse Current ratio (0.04) than 85.71% of its industry peers.
A Quick Ratio of 0.04 indicates that CHS may have some problems paying its short term obligations.
With a Quick ratio value of 0.04, CHS is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
CHS.CA Yearly Current Assets VS Current LiabilitesCHS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.66% over the past year.
Looking at the last year, CHS shows a very negative growth in Revenue. The Revenue has decreased by -10.90% in the last year.
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140.66%
Revenue 1Y (TTM)-10.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0.07%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CHS.CA Yearly Revenue VS EstimatesCHS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 1M 2M 3M 4M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CHS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHS.CA Price Earnings VS Forward Price EarningsCHS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHS.CA Per share dataCHS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CHS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPREHENSIVE HEALTHCARE SYS

TSX-V:CHS (5/2/2025, 7:00:00 PM)

0.015

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.82%
Ins Owner ChangeN/A
Market Cap3.72M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.7
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.02
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -599.1%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.11%
FCFM N/A
ROA(3y)-244.18%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover6.42
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z -71.69
F-ScoreN/A
WACC9.88%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140.66%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.03%
OCF growth 3YN/A
OCF growth 5YN/A